Global Hydroxychloroquine Market Is Growing Rapidly as Sanofi and Teva Pharmaceutical announces to donate millions of doses of Hydroxychloroquine for the treatment of COVID-19
Hydroxychloroquine (Plaquenil and Hydrochloroquin) are commonly used in the treatment of osteoarthritis. Hydroxychloroquine and Hydroxyquinone (Dilantin) are considered "anti-inflammatory" medicines. They inhibit the action of prostaglandins and leukotrienes on the skin, joints, and tendons. It can reduce swelling and pain associated with arthritis. Hydroxychloroquine is in a category of drugs known as "dilators" which were first introduced to control and prevent arthritis from occurring. Hydroxychloroquine (Plaquenil), commonly referred to as "hydroxychloroquine" or "hydroxychloroquin", is an antirheumatic medication that has been used in the treatment of arthritis since its discovery in the 1960s. Hydroxychloroquine is a synthetic compound containing chlorthalidomide and hydroxydimethylammonium chloride. This compound is used to treat arthritis of the knee, hip, forearm, and lower back. It is a strong antacid that causes nausea and vomiting in some patients. The drug is available in oral and injectable form. The oral forms are commonly used in the treatment of osteoarthritis. Injectable Hydroxychloroquine, on the other hand, is injected into the affected joint for faster onset of results. Hydroxychloroquine is typically administered in combination with other medications to achieve faster results. Hydroxyquinone and azathioprine are commonly combined in order to increase the drug's effectiveness.
Increasing prevalence of viral diseases such as malaria and auto-immune diseases including lupus is expected to drive growth of the global hydroxychloroquine market during the forecast period. According to the World Health Organization (WHO), in 2018, there were around 228 million cases of malaria worldwide with over 405,000 deaths. According to the same source, the African region is the most affected region in the world with malaria. According to the Lupus Foundation of America, around 1.5 million U.S. citizens and around 5 million people worldwide suffer from lupus. Hydroxychloroquine is typically used for the treatment of these viral diseases. Hence, these factors are expected to drive growth of the global hydroxychloroquine market during the forecast period. Furthermore, rising R&D activities due to its efficacy against SARS-CoV-2 that causes COVID-19 is expected to boost the global hydroxychloroquine market growth over the forecast period.
However, stringent government regulations and disparity over its use among healthcare professionals are expected to restrain growth of the global hydroxychloroquine market during the forecast period. Among regions, Africa and Southeast Asia are expected to hold a dominant position in the global hydroxychloroquine market during the forecast period. This is owing to rising prevalence of malaria in the region.
Key companies operating in the global hydroxychloroquine market are Sanofi, Zydus Cadila, Bayer AG, Mylan N.V., Teva Pharmaceutical Industries Ltd., and Ipca Laboratories Ltd.
Key companies operating in the global hydroxychloroquine market are Sanofi, Zydus Cadila, Bayer AG, Mylan N.V., Teva Pharmaceutical Industries Ltd., and Ipca Laboratories Ltd.
Comments
Post a Comment